According to the data, ixekizumab was statistically superior to placebo in the treatment of patients with active PsA, as showed by the proportion of patients achieving an ACR
TetraLogic is focused on discovering and developing new small molecule therapeutics in oncology and infectious diseases. As part of the deal, the two firms will conduct an initial
Daiichi Sankyo received around 9% stake in Sun Pharma following the merger of Ranbaxy with the Indian pharmaceutical firm. Under the deal, Ranbaxy shareholders were to receive 0.8
In 2015, the two trials will be examining, RGN-259/GBT201, ReGenTree’s preservative-free eye drops. Each of these eye disorders was being targeted by RegeneRx before entering into the joint
The randomized, double-blind, multicenter, placebo-controlled (2:1) MS-SPI trial evaluated the efficacy and safety of MD1003, 300mg/day, in patients with progressive MS who have showed progression in the two
An ODD has been applied by the company for pediatric high grade gliomas (HGG), however the FDA granted an ODD for the broader indication of malignant glioma in
XMT-1522 is based on the company’s Fleximer immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules. Optimized for payload delivery, the conjugate uses a new
Earlier, Keytruda received breakthrough therapy designation for advanced NSCLC and this sBLA seeks approval to treat these NSCLC patients whose disease has progressed on or after platinum-containing chemotherapy
Several patients with stage IIb to IV malignant melanoma develop cutaneous metastases and samcyprone is being developed to treat these metastases. Samcyprone is a topical formulation of Diphenylcylcopropenone
In uveal melanoma, cancer cells form in the tissues of the eye and it is the most common primary intraocular malignancy in adults and comprises 5% of all
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.